Alopecia-Intellectual Disability Syndrome 1

Mendelian MONDO:0021035 Pathograph 8 Show in embeddings browser

Alopecia-intellectual disability syndrome 1 (APMR1) is a rare autosomal recessive neurocutaneous condition combining total or partial scalp and body hair loss with intellectual disability. The original Pakistani linkage family had congenital generalized alopecia and severe intellectual disability; a later Iranian family with seven affected relatives carried homozygous AHSG p.Arg317His. The historical linkage family was not molecularly resolved in its report, so its complete phenotype is not automatically an AHSG-specific spectrum. AHSG encodes fetuin-A. The reported variant segregates with the phenotype and is associated with altered protein migration, but its biochemical effect and the routes to hair loss and intellectual disability remain unresolved. TGF-beta antagonism and keratinocyte migration are candidate explanations drawn from experiments outside APMR1. The numbered APMR forms are genetically heterogeneous: AHSG is associated with APMR1, LSS with APMR4, and APMR2 and APMR3 denote separate linkage loci. An APMR1-specific population prevalence has not been established.

Ask OpenScientist

Ask a research question about Alopecia-Intellectual Disability Syndrome 1. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
3
Pathophys.
6
Phenotypes
1
Hypotheses
4
Gaps
8
Pathograph
1
Genes
1
Variants
4
Medical Actions
2
Differentials
4
Models
18
References
1
Deep Research
👪

Inheritance

1
Autosomal Recessive HP:0000007
Autosomal recessive inheritance is supported by consanguineous pedigrees. In the AHSG-associated Iranian family, affected relatives were homozygous for p.Arg317His and the variant segregated with the disorder. The earlier Pakistani family established the APMR1 linkage interval without identifying its causal variant.
Autosomal recessive inheritance
Show evidence (3 references)
PMID:28054173 SUPPORT BACKGROUND Human Clinical
"Alopecia with mental retardation syndrome (APMR) is a very rare autosomal recessive condition that is associated with total or partial absence of hair from the scalp and other parts of the body as well as variable intellectual disability."
States both the recessive inheritance pattern and the cardinal two-component phenotype.
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members."
Segregation across seven affected members of one consanguineous kindred is the basis for the recessive model.
PMID:16273389 SUPPORT Human Clinical
"A large seven-generation Pakistani family (Fig. 1), segregating an autosomal recessive form of APMR syndrome, was ascertained in which four males and three females were affected."
Documents the seven affected relatives in the original linkage family.
◈

Mechanistic Hypotheses

1
Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
fetuin_tgfb_antagonism_model EMERGING
Evidence balance 1 support
This candidate model links a possible reduction in fetuin-A antagonism to excessive TGF-beta2 activity and premature follicular catagen. It is an inference from biochemical binding experiments and human follicle organ culture, not an observed effect of p.Arg317His. Neither mutant TGF-beta binding nor excess pathway activity or premature catagen was measured in APMR1. Adult follicle cycling also does not directly explain failure to establish hair at birth. This model addresses the hair phenotype only; fetal fetuin-A expression does not establish a TGF-beta-dependent route to intellectual disability.
Pathograph links
Biallelic AHSG Missense Variant -> Reduced Fetuin-A TGF-beta Antagonism INDIRECT UNKNOWN INTERMEDIATES The model postulates reduced ligand antagonism by variant fetuin-A. The altered electrophoretic migration does not establish this direction of functional change.
Reduced Fetuin-A TGF-beta Antagonism -> Premature Hair Follicle Catagen Entry INDIRECT UNKNOWN INTERMEDIATES Reduced restraint of the experimentally catagen-promoting TGF-beta2 signal could favor premature catagen. Both the loss of restraint and the resulting timing defect remain untested in APMR1.
Premature Hair Follicle Catagen Entry -> Alopecia of Scalp INDIRECT UNKNOWN INTERMEDIATES Premature regression could contribute to hair loss if the candidate mechanism operates in APMR1. The congenital phenotype could instead involve follicle formation or another fetuin-A function.
Show evidence (1 reference)
PMID:12060393 SUPPORT INDIRECT In Vitro
"In the presence of the antibody as well as fetuin, hair follicles were markedly elongated in a concentration-dependent manner."
Supports the candidate hair-cycle mechanism in non-APMR1 organ culture.
?

Discussions and Knowledge Gaps

4
Which functional change connects AHSG p.Arg317His to alopecia and intellectual disability?
KNOWLEDGE GAP OPEN apmr1_ahsg_gene_validity
Attached to
pathophysiology#Biallelic AHSG Missense Variant genetic#AHSG
The association is supported by one extensively segregating family, positional concordance and altered protein migration. The reviewed evidence does not determine whether the variant changes processing, ligand antagonism, cell migration or another function. ClinVar submissions and later reviews are not independent mechanistic replication. The historical linkage family was unresolved at gene level.
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members."
Defines the reported association.
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"In addition, the altered protein migrates with an aberrant size relative to healthy individuals."
Defines the measured biochemical difference without assigning its mechanism.
What do the AHSG-null observations establish about the APMR1 allele?
KNOWLEDGE GAP OPEN apmr1_ahsg_model_scope
Attached to
genetic#AHSG animal_models#Ahsg-null mouse
Ahsg-null mice were assessed principally for calcification, not hair cycling or cognition. A separate nine-week-old infant with homozygous p.Lys2Ter and undetectable circulating fetuin-A had infantile cortical hyperostosis and was followed for one year. The authors explicitly described an association without experimental proof of ICH causation. Neither study provides dedicated negative hair or cognitive testing that rules out loss of function in APMR1 or establishes a neomorphic mechanism. Targeted allele-matched functional and developmental studies are needed.
Show evidence (4 references)
PMID:31288248 SUPPORT Human Clinical
"After 1 year of follow-up, the patient was completely well with no bone deformity and/or elevated inflammatory markers."
Defines the limited clinical follow-up; no formal normal cognition or alopecia exclusion follows from this statement.
PMID:31288248 SUPPORT Human Clinical
"Our study has several limitations; we report only an association between fetuin-A deficiency and ICH phenotype, but no in vivo experiment was conducted in order to prove causation."
The primary authors limit the disease-causation interpretation.
PMID:31288248 SUPPORT Human Clinical
"By enzyme-linked immunosorbent assay (ELISA), we show a complete deficiency of this protein in the patient's serum, compared to controls."
Directly establishes absent circulating protein in this separate infant case.
+ 1 more reference
Do fetuin-A expression and keratinocyte migration explain the congenital hair and cognitive findings?
KNOWLEDGE GAP OPEN apmr1_developmental_routes
Attached to
phenotypes#Alopecia of Scalp phenotypes#Intellectual Disability
Normal fetal plasma/CSF concentrations and skin-cell migration effects support developmental plausibility, but neither demonstrates a necessary role in human neocortical development or follicular placode formation. The primary keratinocyte study examined newborn foreskin and adult skin, not human fetal placode development. Its primary-cell and HaCaT responses to EGFR blockade differ. These observations motivate alternatives to the hair-cycle hypothesis without establishing an APMR1-specific route.
Show evidence (4 references)
PMID:7680865 SUPPORT Human Clinical
"The concentration of alpha 2HS-glycoprotein (alpha 2HS), a human homologue of the fetal protein fetuin, has been measured in plasma and cerebrospinal fluid (CSF) of fetuses from 14 to 37 weeks of gestation and in cord blood from newborn babies."
Primary developmental concentration study; expression is not causal evidence of neocortical malformation.
PMID:7680865 SUPPORT Human Clinical
"The levels were highest in both plasma and CSF in the younger fetuses, but even in the newborn the concentration of alpha 2HS in plasma was nearly twice the adult level."
Defines the observed age-related concentration pattern.
PMID:19758338 SUPPORT Human Clinical
"In this study, we found that in human newborn foreskin, a high level of fetuin-A protein is detected throughout the dermis."
Identifies the actual human tissue and stage studied.
+ 1 more reference
Which gene or locus belongs to each numbered APMR form?
INTERPRETATION RESOLVED apmr1_locus_series_confusion
Attached to
disease#Alopecia-Intellectual Disability Syndrome 1
APMR1 was mapped to 3q26.33-q27.3 and later associated with AHSG at 3q27.3. APMR2 is a non-overlapping chromosome 3 locus; APMR3 maps to chromosome 18; LSS-related APMR4 maps to chromosome 21. Findings from the different families require their own subtype and gene attribution.
Resolution: The entry retains APMR1 as a distinct disease and the existing APMR grouping. Unidentified genes do not prevent disease curation, and the numbered forms are not all on different chromosomes.
Show evidence (2 references)
PMID:16922726 SUPPORT Human Clinical
"The linkage interval of the APMR locus identified here does not overlap with the one described previously; therefore, this locus has been designated as APMR2."
Separates the two chromosome 3 loci.
PMID:33881165 SUPPORT REVIEW SYNTHESIS Other
"Among them, AHSG was reported in a consanguineous Iranian family and LSS gene in a Swiss origin family, while the remaining two uncharacterized loci, that is, APMR2 and APMR3, are reported in the Pakistani population."
Review of the distinct gene/locus assignments.
⚙

Pathophysiology

3
Biallelic AHSG Missense Variant
Mechanism confidence: Provisional
Homozygous AHSG c.950G>A (p.Arg317His) was reported in seven affected members of one consanguineous Iranian family. AHSG lies within the independently mapped APMR1 interval. The clinical association is supported by segregation, positional evidence and altered protein migration, but the direction of protein dysfunction and tissue mechanisms are unresolved.
Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
AHSG hgnc:349 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves AHSG (hgnc:349). hgnc:349 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Alopecia of Scalp The reported AHSG association provides an unresolved route to this clinical finding. The intervening developmental and cellular mechanisms are not established.
Intellectual Disability The reported AHSG association provides an unresolved route to this clinical finding. The intervening developmental and cellular mechanisms are not established.
Reduced Fetuin-A TGF-beta Antagonism The model postulates reduced ligand antagonism by variant fetuin-A. The altered electrophoretic migration does not establish this direction of functional change. Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His)."
Identifies the reported candidate allele and zygosity.
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Consistent with the phenotype, AHSG maps within APMR linkage region 1 (APMR 1) as reported before, and falls within runs of homozygosity (ROH)."
Places the variant within the linked region; positional concordance alone does not prove causation.
Reduced Fetuin-A TGF-beta Antagonism
Mechanism confidence: Hypothetical
Reduced antagonism of TGF-beta ligands is a proposed consequence of the APMR1 allele. Normal fetuin binds TGF-beta/BMP ligands in vitro, but deficient binding or neutralization has not been demonstrated for p.Arg317His. This node is conditional on the stated hypothesis.
Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512). GO:0030512 is a biological process from the Gene Ontology.
Downstream
Premature Hair Follicle Catagen Entry Reduced restraint of the experimentally catagen-promoting TGF-beta2 signal could favor premature catagen. Both the loss of restraint and the resulting timing defect remain untested in APMR1. Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
Show evidence (1 reference)
PMID:8662721 SUPPORT INDIRECT In Vitro
"Surface plasmon resonance measurements show that fetuin binds directly to TGF-beta1 and TGF-beta2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6)."
Establishes normal ligand binding, not a loss of this activity in APMR1.
Premature Hair Follicle Catagen Entry
Mechanism confidence: Hypothetical
Premature follicular regression is a candidate explanation for hair loss based on human hair-cycle experiments. TGF-beta2 suppressed elongation, whereas fetuin and neutralizing antibody promoted elongation in organ culture. These experiments did not study an AHSG-variant follicle or demonstrate premature catagen in APMR1 skin.
Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
hair follicle cell CL:0002559 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hair follicle cell (CL:0002559). CL:0002559 is a cell type from the Cell Ontology.
Experimental models
Human hair follicle organ culture with TGF-beta2 and fetuin OTHER Manipulates a ligand implicated in normal human catagen and measures hair elongation.
Downstream
Alopecia of Scalp Premature regression could contribute to hair loss if the candidate mechanism operates in APMR1. The congenital phenotype could instead involve follicle formation or another fetuin-A function. Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
Show evidence (1 reference)
PMID:12060393 SUPPORT INDIRECT In Vitro
"Elongation of hair was significantly suppressed by transforming growth factor-beta2."
Shows the direction of the experimental ligand effect, not the cause of congenital APMR1 alopecia.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Alopecia-Intellectual Disability Syndrome 1 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Head and Neck 3
Alopecia of Scalp HP:0002293 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Alopecia of scalp (HP:0002293). HP:0002293 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28054173 SUPPORT BACKGROUND Human Clinical
"associated with total or partial absence of hair from the scalp and other parts of the body"
Supports variable extent of hair loss.
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Directly documents congenital scalp alopecia in the linkage family.
Absent Eyebrow HP:0002223 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent eyebrow (HP:0002223). HP:0002223 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3 study.
Absent Eyelashes HP:0000561 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent eyelashes (HP:0000561). HP:0000561 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3 study.
Integument 2
Absent Axillary Hair HP:0002221 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent axillary hair (HP:0002221). HP:0002221 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3 study.
Absent Pubic Hair HP:0002555 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent pubic hair (HP:0002555). HP:0002555 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3 study.
Nervous System 1
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
The linkage report found normal hearing, teeth, nails and sweating, no seizures, and normal gross motor development in the two relatives examined neurologically. These limited negative observations do not exclude such findings across APMR1. Broad APMR reviews mentioning epilepsy and delay do not provide sufficiently specific AHSG-family data to establish their frequency here.
Show evidence (5 references)
PMID:28054173 SUPPORT BACKGROUND Human Clinical
"as well as variable intellectual disability"
Supports the cognitive component of the syndrome.
PMID:16273389 SUPPORT Human Clinical
"In addition, all the affected individuals were similarly severely mentally retarded and were described as difficult to handle."
Directly describes the original linkage family.
url:https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf SUPPORT REVIEW SYNTHESIS Other
"3(q27) 40to54 AHSG Alpha-2-HS- glycoprotein"
Table 1 associates the IQ range with the Iranian AHSG family; this is a secondary summary.
+ 2 more references
🧬

Genetic Associations

1
AHSG
Gene: AHSG hgnc:349 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AHSG (hgnc:349). hgnc:349 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members."
Defines the ascertainment supporting the reported association.
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His)."
Specifies the reported homozygous allele.
Variants (1)
NM_001622.4:c.950G>A (p.Arg317His) Likely Pathogenic
Gene: AHSG hgnc:349 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in AHSG (hgnc:349). hgnc:349 is a gene from the HUGO Gene Nomenclature Committee. missense
Homozygous missense variant reported with APMR1. The original report called it predicted pathogenic. The LIKELY_PATHOGENIC value here records the ClinVar RCV000578120.9 aggregate classification, last evaluated March 24, 2026, rather than a new curator ACMG classification. The record has two submissions but criteria from one submitter; this is not evidence of two independently phenotyped APMR1 families. Protein migration is altered, while the functional direction remains unresolved.
Identifiers: dbSNP:rs201849460
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His)."
Primary association and zygosity.
url:https://www.ncbi.nlm.nih.gov/clinvar/RCV000578120/ SUPPORT Other
"It is classified as likely pathogenic according to the recommendations of ACMG/AMP/ClinGen SVI guidelines."
The criteria-providing ClinVar submitter explicitly assigns likely pathogenic. The surrounding comment mis-cites the APMR3 paper for the historical family, so it is used for its database assertion only, not as new clinical evidence.
💊

Medical Actions

4
Individualized developmental and educational support
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Behavioral / lifestyle
Assess individual adaptive, communication and learning needs and provide early developmental support, communication therapy and educational accommodations as appropriate. Planning should continue into vocational and adult independent-living support. These measures are extrapolated from general intellectual-disability guidance; APMR1-specific efficacy has not been established.
Show evidence (2 references)
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Nonetheless, the postnatal early intervention plan should include accurate diagnosis of ID and comorbid conditions; identification of underlying etiological processes and methods of treatment as applicable; and activities to facilitate sensory-motor integration, speech and language development,..."
General ID guidance supports individualized early intervention rather than an APMR1-specific treatment effect.
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Nonpharmacological intervention should focus on skill development leading to educational and vocational competencies so that the individual will acquire necessary capacities for future adult independent living."
Supports continued functional skill development.
Genetic counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Discuss the recessive pedigree, segregation testing and reproductive options using the familial molecular finding when clinically established. Interpretation should include the limited AHSG gene-disease evidence; identifying any pair of rare AHSG variants does not itself confirm the diagnosis.
Show evidence (2 references)
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Genetic counseling not only provides accurate information on the prognosis of disorders and recurrence risks, but also helps in removing guilt and allaying ongoing recrimination in families."
General genetic counseling recommendation applied to this rare recessive presentation.
PMID:28054173 SUPPORT INDIRECT PRIMARY RESULT Human Clinical
"Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members."
Provides the relevant family segregation context.
Scalp and eye protection for hair loss
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Protect exposed scalp skin with a hat or appropriate sunscreen, and consider glasses or other protection when eyelashes or eyebrows are absent. These practical measures are extrapolated from dermatology guidance for alopecia areata; they address loss of hair protection and do not imply shared immune pathogenesis or efficacy of alopecia-areata drugs in APMR1.
Show evidence (3 references)
url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care SUPPORT INDIRECT Other
"Wear a wide-brimmed hat or wig when outdoors."
General hair-loss protection guidance applied to exposed scalp skin.
url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care SUPPORT INDIRECT Other
"If you don’t cover your head, apply sunscreen to your scalp."
Supports sun protection of a hairless scalp.
url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care SUPPORT INDIRECT Other
"Wear a hat, sweatband, or glasses."
This recommendation occurs under eye protection after loss of eyelashes or eyebrows.
Family support and individualized behavioral care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Offer family support and address behavioral or mental-health needs when present. Changes in behavior should prompt assessment for treatable contributors rather than being automatically attributed to intellectual disability. The guidance is general to intellectual disability and does not establish a characteristic psychiatric phenotype in APMR1.
Show evidence (2 references)
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Each family is unique therefore the family support programmes must be individualized to meet the needs of the family in the context of care-giving and disability impact."
Supports individualized family services.
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"Any changes in behavior compared to previous period, dip in overall functioning, and changes in vegetative functioning should be carefully recorded in each visit."
Supports review of new behavioral or functional changes.
🔬

Biochemical Markers

1
Altered fetuin-A electrophoretic migration (PRESENT)
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"In addition, the altered protein migrates with an aberrant size relative to healthy individuals."
Reports the observed protein migration difference.
PMID:28054173 SUPPORT PRIMARY RESULT Computational
"The variant is predicted to affect a region of the protein required for protein processing and disrupts a phosphorylation motif."
The proposed processing/phosphorylation effect is a prediction.
🔬

Diagnosis

2
Clinical and developmental assessment
Document the onset and distribution of alopecia together with intellectual and adaptive functioning, pedigree and other ectodermal or neurologic findings. Clinical overlap requires consideration of other inherited alopecia-intellectual disability syndromes.
Show evidence (2 references)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Directly documents the hair phenotype of the original linkage family.
PMID:30745696 SUPPORT INDIRECT REVIEW SYNTHESIS Other
"The diagnostic process involves history taking, observation including medical examination, intellectual and adaptive behavioral assessment, identification of comorbid psychiatric disorders, and need-based laboratory investigations for other medical conditions."
General ID assessment guidance; no APMR1-specific diagnostic score is established.
Molecular genetic evaluation
Exome sequencing and family segregation analysis identified AHSG p.Arg317His in the reported family. In a new patient, assess the full clinical and genetic differential and interpret AHSG variants in light of the limited association evidence. The altered protein migration is a research finding rather than a validated standalone diagnostic assay.
molecular genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: A compatible phenotype with a carefully interpreted familial AHSG finding may support APMR1; rare biallelic variants alone are insufficient.
Show evidence (2 references)
PMID:28054173 SUPPORT PRIMARY RESULT Human Clinical
"Our study is the first report to identify a homozygous missense mutation for APMR syndrome through whole-exome sequencing."
Describes the research identification method, not diagnostic sensitivity or universal confirmatory criteria.
PMID:28054173 SUPPORT BACKGROUND Human Clinical
"Previous families with APMR syndrome have been studied through linkage analyses and the linkage resolution did not allow pointing out to a single gene candidate."
Explains why historical linkage families cannot automatically be treated as molecularly confirmed AHSG cases.
📈

Progression

1
Congenital hair phenotype and developmental assessment
Scalp hair was absent from birth in the original APMR1 linkage family. Intellectual disability was identified during clinical assessment. This report does not establish the onset or longitudinal course for all people with AHSG variants, and body sites that normally acquire hair at puberty require age-appropriate interpretation.
Show evidence (2 references)
PMID:16273389 SUPPORT Human Clinical
"In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair."
Directly supports congenital scalp alopecia in the linkage family; it does not supply age-specific denominators for axillary or pubic hair.
PMID:16273389 SUPPORT Human Clinical
"In addition, all the affected individuals were similarly severely mentally retarded and were described as difficult to handle."
Documents developmental impairment in the ascertained family without proving a progressive course.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Alopecia-Intellectual Disability Syndrome 1:

Alopecia-Intellectual Disability Syndrome 4 MONDO:0030009
Overlapping Features LSS-related APMR4 shares congenital alopecia and intellectual disability. Developmental delay, epilepsy and additional findings occur in reported LSS cases; molecular testing distinguishes the conditions, while individual associated features are not absolute discriminators.
Show evidence (2 references)
PMID:38800572 SUPPORT BACKGROUND Human Clinical
"It is characterized by congenital alopecia and variable degrees of intellectual disability (ID), frequently associated with developmental delay (DD) and epilepsy."
Describes the overlapping APMR4 spectrum.
PMID:38800572 SUPPORT Human Clinical
"Two novel LSS variants (c.401 T > G and c.369C > G) were detected with whole-exome sequencing (WES)."
Supplies the different gene in the reported case.
Atrichia with Papular Lesions Not Yet Curated MONDO:0008847
Overlapping Features HR-related atrichia can cause extensive early hair loss. Hair loss soon after birth followed by a diffuse papular rash is a distinguishing pattern; evaluation of the cognitive phenotype and molecular findings is needed when APMR1 is considered.
Show evidence (2 references)
PMID:10504459 SUPPORT Human Clinical
"Atrichia with papular lesions is a rare autosomal recessive form of alopecia characterized by hair loss soon after birth and the development during childhood of a diffuse papular rash."
Supports the distinguishing timing and skin findings.
PMID:10504459 SUPPORT Human Clinical
"In this report, we describe a novel nonsense mutation in exon 4 of the human hairless gene in a consanguineous kindred affected with atrichia with papular lesions."
Directly supports HR as the causal gene for this differential.
🧫

Experimental Models

3
Human hair follicle organ culture with TGF-beta2 and fetuin OTHER
TGF-beta2 suppressed hair elongation, while neutralizing antibody and fetuin promoted elongation in organ culture. This experiments with a candidate hair-cycle pathway but does not reproduce the APMR1 allele or congenital follicle development.
Organism
Homo sapiens NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Human hair follicles; no APMR1 genotype tested
Publication
PMID:12060393
Pathograph links
Premature Hair Follicle Catagen Entry perturbs fidelity: low observes: tissue Manipulates a ligand implicated in normal human catagen and measures hair elongation.
Limitations: The measured elongation response is not demonstration of premature catagen in APMR1 or rescue of a mutant follicle.
Show evidence (2 references)
PMID:12060393 SUPPORT In Vitro
"In the presence of the antibody as well as fetuin, hair follicles were markedly elongated in a concentration-dependent manner."
Reports the experimental elongation response.
+ 1 more reference
Show evidence (1 reference)
PMID:12060393 SUPPORT In Vitro
"These results strongly suggest that transforming growth factor-beta2 plays an essential part in the induction of the catagen phase of the human hair cycle."
Supports the hair-cycle context.
Fetuin ligand binding and cytokine antagonism assays OTHER
Surface plasmon resonance measured fetuin binding to TGF-beta and BMP ligands; competitive ELISA tested interference with TGF-beta1 receptor binding. These are biochemical experiments on fetuin function, without the APMR1 variant.
Publication
PMID:8662721
The results make altered ligand antagonism a testable candidate, but do not measure loss of antagonism by p.Arg317His.
Show evidence (1 reference)
PMID:8662721 SUPPORT In Vitro
"Surface plasmon resonance measurements show that fetuin binds directly to TGF-beta1 and TGF-beta2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6)."
Direct biochemical binding measurements.
Primary human keratinocyte and HaCaT migration cultures PRIMARY_CELL_CULTURE
Fetuin-A induced actin-rich protrusions and promoted wound closure. EGF receptor blockade had limited effects on the primary-cell response but substantially inhibited the HaCaT response. This provides an alternative cell-migration rationale outside APMR1, not evidence of impaired placode formation or mutant rescue.
Organism
Homo sapiens NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Primary human keratinocytes and parallel immortalized HaCaT cultures
Publication
PMID:19758338
Show evidence (2 references)
PMID:19758338 SUPPORT In Vitro
"Fetuin-A significantly induces actin-rich protrusions in human primary keratinocytes."
Documents the primary-cell morphology response.
PMID:19758338 SUPPORT In Vitro
"Interestingly, blockade of epidermal growth factor (EGF) receptor signalling has a limited effect on fetuin-A promoted 'wound closure' on primary human keratinocytes, but significantly inhibits fetuin-A's effect on HaCaT cells."
Separates primary-cell and immortalized-cell signaling results.
🐁

Animal Models

1
Ahsg-null mouse
Constitutive Ahsg-null mice were studied for ectopic mineralization. Severe systemic calcification depended strongly on DBA/2 genetic background or a mineral/vitamin-D challenge, while the mixed or C57BL/6 background had less marked spontaneous disease. The study did not perform targeted follicle, hair-cycle or cognitive testing and is not a matched p.Arg317His APMR1 model.
Species
Mouse
Genotype
Ahsg-/- (targeted null)
Background
C57BL/6 and DBA/2
Genes
AHSG hgnc:349 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns AHSG (hgnc:349). hgnc:349 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:12897203
A general description of untreated mice as having no obvious abnormalities is not a measured negative result for alopecia or intellectual disability. These data establish fetuin-A mineralization biology without choosing among possible APMR1 mechanisms.
Show evidence (2 references)
PMID:12897203 SUPPORT Model Organism
"Ahsg-deficient mice are phenotypically normal, but develop severe calcification of various organs on a mineral and vitamin D-rich diet and on a normal diet when the deficiency is combined with a DBA/2 genetic background."
Captures the background- and exposure-dependent mineralization phenotype; it supplies no dedicated hair or cognitive assessment.
PMID:12897203 SUPPORT Model Organism
"These mice in the untreated state have no obvious abnormalities, but alizarin red staining of skeletal preparations revealed the existence of soft-tissue calcification in some female Ahsg-deficient ex-breeders."
The reported baseline assessment is general and already includes subtle mineralization.
{ }

Source YAML

click to show 
name: Alopecia-Intellectual Disability Syndrome 1
synonyms:
- APMR1
- Alopecia with mental retardation syndrome 1
- AHSG-related alopecia-intellectual disability syndrome
- Alopecia-intellectual disability syndrome type 1
creation_date: '2026-08-26T09:00:00Z'
category: Mendelian
description: >-
  Alopecia-intellectual disability syndrome 1 (APMR1) is a rare autosomal recessive neurocutaneous condition
  combining total or partial scalp and body hair loss with intellectual disability. The original Pakistani
  linkage family had congenital generalized alopecia and severe intellectual disability; a later Iranian
  family with seven affected relatives carried homozygous AHSG p.Arg317His. The historical linkage family
  was not molecularly resolved in its report, so its complete phenotype is not automatically an AHSG-specific
  spectrum.

  AHSG encodes fetuin-A. The reported variant segregates with the phenotype and is associated with altered
  protein migration, but its biochemical effect and the routes to hair loss and intellectual disability
  remain unresolved. TGF-beta antagonism and keratinocyte migration are candidate explanations drawn from
  experiments outside APMR1. The numbered APMR forms are genetically heterogeneous: AHSG is associated
  with APMR1, LSS with APMR4, and APMR2 and APMR3 denote separate linkage loci. An APMR1-specific population
  prevalence has not been established.
disease_term:
  preferred_term: alopecia-intellectual disability syndrome 1
  term:
    id: MONDO:0021035
    label: alopecia-intellectual disability syndrome 1
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Autosomal recessive inheritance is supported by consanguineous pedigrees. In the AHSG-associated
    Iranian family, affected relatives were homozygous for p.Arg317His and the variant segregated with
    the disorder. The earlier Pakistani family established the APMR1 linkage interval without identifying
    its causal variant.
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Alopecia with mental retardation syndrome (APMR) is a very rare autosomal recessive condition that is associated with total or partial absence of hair from the scalp and other parts of the body as well as variable intellectual disability.
    explanation: States both the recessive inheritance pattern and the cardinal two-component phenotype.
    quote_role: BACKGROUND
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
    explanation: Segregation across seven affected members of one consanguineous kindred is the basis for the recessive model.
    quote_role: PRIMARY_RESULT
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A large seven-generation Pakistani family (Fig. 1), segregating an autosomal recessive form of APMR syndrome, was ascertained in which four males and three females were affected.
    explanation: >-
      Documents the seven affected relatives in the original linkage family.
mechanistic_hypotheses:
- hypothesis_group_id: fetuin_tgfb_antagonism_model
  hypothesis_label: Reduced fetuin-A antagonism of hair-cycle TGF-beta signaling
  status: EMERGING
  description: >-
    This candidate model links a possible reduction in fetuin-A antagonism to excessive TGF-beta2 activity
    and premature follicular catagen. It is an inference from biochemical binding experiments and human
    follicle organ culture, not an observed effect of p.Arg317His. Neither mutant TGF-beta binding nor
    excess pathway activity or premature catagen was measured in APMR1. Adult follicle cycling also
    does not directly explain failure to establish hair at birth. This model addresses the hair phenotype
    only; fetal fetuin-A expression does not establish a TGF-beta-dependent route to intellectual disability.
  evidence:
  - reference: PMID:12060393
    reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In the presence of the antibody as well as fetuin, hair follicles were markedly elongated in a concentration-dependent manner.
    explanation: >-
      Supports the candidate hair-cycle mechanism in non-APMR1 organ culture.
    directness: INDIRECT
pathophysiology:
- name: Biallelic AHSG Missense Variant
  role: trigger
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    Homozygous AHSG c.950G>A (p.Arg317His) was reported in seven affected members of one consanguineous
    Iranian family. AHSG lies within the independently mapped APMR1 interval. The clinical association
    is supported by segregation, positional evidence and altered protein migration, but the direction
    of protein dysfunction and tissue mechanisms are unresolved.
  gene:
    preferred_term: AHSG
    term:
      id: hgnc:349
      label: AHSG
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His).'
    explanation: >-
      Identifies the reported candidate allele and zygosity.
    quote_role: PRIMARY_RESULT
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Consistent with the phenotype, AHSG maps within APMR linkage region 1 (APMR 1) as reported before, and falls within runs of homozygosity (ROH).
    explanation: >-
      Places the variant within the linked region; positional concordance alone does not prove causation.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Alopecia of Scalp
    description: >-
      The reported AHSG association provides an unresolved route to this clinical finding. The intervening
      developmental and cellular mechanisms are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
      explanation: >-
        Family segregation supports the provisional gene-disease relationship; it does not identify
        the intermediate mechanism.
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: associated with total or partial absence of hair from the scalp and other parts of the body
      explanation: >-
        Identifies the clinical outcome associated with the syndrome.
      directness: INDIRECT
      quote_role: BACKGROUND
  - target: Intellectual Disability
    description: >-
      The reported AHSG association provides an unresolved route to this clinical finding. The intervening
      developmental and cellular mechanisms are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
      explanation: >-
        Family segregation supports the provisional gene-disease relationship; it does not identify
        the intermediate mechanism.
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: as well as variable intellectual disability
      explanation: >-
        Identifies the clinical outcome associated with the syndrome.
      directness: INDIRECT
      quote_role: BACKGROUND
  - target: Reduced Fetuin-A TGF-beta Antagonism
    description: >-
      The model postulates reduced ligand antagonism by variant fetuin-A. The altered electrophoretic
      migration does not establish this direction of functional change.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - fetuin_tgfb_antagonism_model
    evidence:
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In addition, the altered protein migrates with an aberrant size relative to healthy individuals.
      explanation: >-
        An altered protein product motivates functional testing but does not demonstrate deficient
        antagonism.
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
    - reference: PMID:8662721
      reference_title: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Surface plasmon resonance measurements show that fetuin binds directly to TGF-beta1 and TGF-beta2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6).
      explanation: >-
        Normal fetuin binding supplies biological plausibility for the hypothesis, without testing
        the APMR1 variant.
      directness: INDIRECT
- name: Reduced Fetuin-A TGF-beta Antagonism
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Reduced antagonism of TGF-beta ligands is a proposed consequence of the APMR1 allele. Normal fetuin
    binds TGF-beta/BMP ligands in vitro, but deficient binding or neutralization has not been demonstrated
    for p.Arg317His. This node is conditional on the stated hypothesis.
  biological_processes:
  - preferred_term: negative regulation of transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0030512
      label: negative regulation of transforming growth factor beta receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:8662721
    reference_title: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Surface plasmon resonance measurements show that fetuin binds directly to TGF-beta1 and TGF-beta2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6).
    explanation: >-
      Establishes normal ligand binding, not a loss of this activity in APMR1.
    directness: INDIRECT
  downstream:
  - target: Premature Hair Follicle Catagen Entry
    description: >-
      Reduced restraint of the experimentally catagen-promoting TGF-beta2 signal could favor premature
      catagen. Both the loss of restraint and the resulting timing defect remain untested in APMR1.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - fetuin_tgfb_antagonism_model
    evidence:
    - reference: PMID:12060393
      reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: These results strongly suggest that transforming growth factor-beta2 plays an essential part in the induction of the catagen phase of the human hair cycle.
      explanation: >-
        Supports the TGF-beta2/catagen relationship in human follicles; its disruption by AHSG p.Arg317His
        is inferred.
      directness: INDIRECT
- name: Premature Hair Follicle Catagen Entry
  biological_scale: TISSUE
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Premature follicular regression is a candidate explanation for hair loss based on human hair-cycle
    experiments. TGF-beta2 suppressed elongation, whereas fetuin and neutralizing antibody promoted
    elongation in organ culture. These experiments did not study an AHSG-variant follicle or demonstrate
    premature catagen in APMR1 skin.
  cell_types:
  - preferred_term: hair follicle cell
    term:
      id: CL:0002559
      label: hair follicle cell
  evidence:
  - reference: PMID:12060393
    reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Elongation of hair was significantly suppressed by transforming growth factor-beta2.
    explanation: >-
      Shows the direction of the experimental ligand effect, not the cause of congenital APMR1 alopecia.
    directness: INDIRECT
  downstream:
  - target: Alopecia of Scalp
    description: >-
      Premature regression could contribute to hair loss if the candidate mechanism operates in APMR1.
      The congenital phenotype could instead involve follicle formation or another fetuin-A function.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - fetuin_tgfb_antagonism_model
    evidence:
    - reference: PMID:12060393
      reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In the presence of the antibody as well as fetuin, hair follicles were markedly elongated in a concentration-dependent manner.
      explanation: >-
        Provides experimental hair-growth evidence for the hypothesis only.
      directness: INDIRECT
phenotypes:
- name: Alopecia of Scalp
  category: Clinical
  description: >-
    Total or partial scalp alopecia is the defining hair finding. Complete absence from birth was documented
    in the original Pakistani linkage family; the AHSG report describes total or partial hair loss without
    an onset statement in its accessible abstract.
  phenotype_term:
    preferred_term: Alopecia of scalp
    term:
      id: HP:0002293
      label: Alopecia of scalp
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: associated with total or partial absence of hair from the scalp and other parts of the body
    explanation: >-
      Supports variable extent of hair loss.
    quote_role: BACKGROUND
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Directly documents congenital scalp alopecia in the linkage family.
- name: Absent Eyebrow
  category: Clinical
  description: >-
    Eyebrows were reported absent in the original APMR1 linkage family. This is a family-specific finding;
    the paper did not establish an AHSG genotype.
  phenotype_term:
    preferred_term: Absent eyebrow
    term:
      id: HP:0002223
      label: Absent eyebrow
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3
      study.
- name: Absent Eyelashes
  category: Clinical
  description: >-
    Eyelashes were reported absent in the original APMR1 linkage family. This is a family-specific finding;
    the paper did not establish an AHSG genotype.
  phenotype_term:
    preferred_term: Absent eyelashes
    term:
      id: HP:0000561
      label: Absent eyelashes
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3
      study.
- name: Absent Axillary Hair
  category: Clinical
  description: >-
    Axillary hair was reported absent in the original APMR1 linkage family. This is a family-specific
    finding; the paper did not establish an AHSG genotype. Age-specific denominators are unavailable,
    so no congenital onset or frequency is assigned to this pubertal hair site.
  phenotype_term:
    preferred_term: Absent axillary hair
    term:
      id: HP:0002221
      label: Absent axillary hair
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3
      study.
- name: Absent Pubic Hair
  category: Clinical
  description: >-
    Pubic hair was reported absent in the original APMR1 linkage family. This is a family-specific finding;
    the paper did not establish an AHSG genotype. Age-specific denominators are unavailable, so no congenital
    onset or frequency is assigned to this pubertal hair site.
  phenotype_term:
    preferred_term: Absent pubic hair
    term:
      id: HP:0002555
      label: Absent pubic hair
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Direct clinical evidence from the APMR1 linkage family rather than an introduction to an APMR3
      study.
- name: Intellectual Disability
  category: Clinical
  description: >-
    Intellectual disability was described as severe in the original Pakistani linkage family. The AHSG-associated
    family had variable intellectual disability; the 2021 review summarizes IQ values of 40–54 for its
    seven relatives. These ascertained families do not establish population frequencies or a uniform
    severity, and molecular equivalence of the linkage family remains unproven.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: as well as variable intellectual disability
    explanation: >-
      Supports the cognitive component of the syndrome.
    quote_role: BACKGROUND
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, all the affected individuals were similarly severely mentally retarded and were described as difficult to handle.
    explanation: >-
      Directly describes the original linkage family.
  - reference: url:https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
    reference_title: https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 3(q27) 40to54 AHSG Alpha-2-HS- glycoprotein
    explanation: >-
      Table 1 associates the IQ range with the Iranian AHSG family; this is a secondary summary.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Affected individuals showed normal hearing, teeth and nails and no abnormalities in sweating were observed.
    explanation: >-
      Documents the family-specific negative observations.
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological examination of two of the affected individuals showed no abnormality; in particular, gross motor development was normal and they never received physiotherapeutic treatment. No other clinical signs including seizures were detected.
    explanation: >-
      Scopes the neurologic findings to two examined relatives and the reported family.
  notes: >-
    The linkage report found normal hearing, teeth, nails and sweating, no seizures, and normal gross
    motor development in the two relatives examined neurologically. These limited negative observations
    do not exclude such findings across APMR1. Broad APMR reviews mentioning epilepsy and delay do not
    provide sufficiently specific AHSG-family data to establish their frequency here.
genetic:
- name: AHSG
  gene_term:
    preferred_term: AHSG
    term:
      id: hgnc:349
      label: AHSG
  relationship_type: CAUSATIVE
  presence: PRESENT
  variant_origin: GERMLINE
  variants:
  - name: NM_001622.4:c.950G>A (p.Arg317His)
    identifiers:
    - dbSNP:rs201849460
    description: >-
      Homozygous missense variant reported with APMR1. The original report called it predicted pathogenic.
      The LIKELY_PATHOGENIC value here records the ClinVar RCV000578120.9 aggregate classification,
      last evaluated March 24, 2026, rather than a new curator ACMG classification. The record has
      two submissions but criteria from one submitter; this is not evidence of two independently phenotyped
      APMR1 families. Protein migration is altered, while the functional direction remains unresolved.
    gene:
      preferred_term: AHSG
      term:
        id: hgnc:349
        label: AHSG
    type: missense
    clinical_significance: LIKELY_PATHOGENIC
    evidence:
    - reference: PMID:28054173
      reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His).'
      explanation: >-
        Primary association and zygosity.
      quote_role: PRIMARY_RESULT
    - reference: url:https://www.ncbi.nlm.nih.gov/clinvar/RCV000578120/
      reference_title: NM_001622.4(AHSG):c.950G>A (p.Arg317His) AND Alopecia-intellectual disability syndrome 1 - ClinVar - NCBI
      supports: SUPPORT
      evidence_source: OTHER
      snippet: It is classified as likely pathogenic according to the recommendations of ACMG/AMP/ClinGen SVI guidelines.
      explanation: >-
        The criteria-providing ClinVar submitter explicitly assigns likely pathogenic. The surrounding
        comment mis-cites the APMR3 paper for the historical family, so it is used for its database
        assertion only, not as new clinical evidence.
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
    explanation: >-
      Defines the ascertainment supporting the reported association.
    quote_role: PRIMARY_RESULT
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'Our study revealed a novel predicted pathogenic, homozygous missense mutation in the AHSG (OMIM 138680) gene (AHSG: NM_001622:exon7:c.950G>A:p.Arg317His).'
    explanation: >-
      Specifies the reported homozygous allele.
    quote_role: PRIMARY_RESULT
  notes: >-
    The reviewed primary association is one consanguineous Iranian family carrying p.Arg317His. The
    historical Pakistani linkage family supports the interval but was not shown to carry this variant.
    AHSG-related APMR1 should be distinguished from LSS-related APMR4 and HR-related inherited atrichia.
    The available data do not establish a loss-of-function, gain-of-function or dominant-negative direction
    for the APMR1 allele.
animal_models:
- name: Ahsg-null mouse
  species: Mouse
  genotype: Ahsg-/- (targeted null)
  background: C57BL/6 and DBA/2
  publication: PMID:12897203
  description: >-
    Constitutive Ahsg-null mice were studied for ectopic mineralization. Severe systemic calcification
    depended strongly on DBA/2 genetic background or a mineral/vitamin-D challenge, while the mixed
    or C57BL/6 background had less marked spontaneous disease. The study did not perform targeted follicle,
    hair-cycle or cognitive testing and is not a matched p.Arg317His APMR1 model.
  genes:
  - preferred_term: AHSG
    term:
      id: hgnc:349
      label: AHSG
  evidence:
  - reference: PMID:12897203
    reference_title: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Ahsg-deficient mice are phenotypically normal, but develop severe calcification of various organs on a mineral and vitamin D-rich diet and on a normal diet when the deficiency is combined with a DBA/2 genetic background.
    explanation: >-
      Captures the background- and exposure-dependent mineralization phenotype; it supplies no dedicated
      hair or cognitive assessment.
  - reference: PMID:12897203
    reference_title: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: These mice in the untreated state have no obvious abnormalities, but alizarin red staining of skeletal preparations revealed the existence of soft-tissue calcification in some female Ahsg-deficient ex-breeders.
    explanation: >-
      The reported baseline assessment is general and already includes subtle mineralization.
  notes: >-
    A general description of untreated mice as having no obvious abnormalities is not a measured negative
    result for alopecia or intellectual disability. These data establish fetuin-A mineralization biology
    without choosing among possible APMR1 mechanisms.
treatments:
- name: Individualized developmental and educational support
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  therapeutic_modality: BEHAVIORAL
  description: >-
    Assess individual adaptive, communication and learning needs and provide early developmental support,
    communication therapy and educational accommodations as appropriate. Planning should continue into
    vocational and adult independent-living support. These measures are extrapolated from general intellectual-disability
    guidance; APMR1-specific efficacy has not been established.
  evidence:
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, the postnatal early intervention plan should include accurate diagnosis of ID and comorbid conditions; identification of underlying etiological processes and methods of treatment as applicable; and activities to facilitate sensory-motor integration, speech and language development, and socioemotional development.
    explanation: >-
      General ID guidance supports individualized early intervention rather than an APMR1-specific
      treatment effect.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonpharmacological intervention should focus on skill development leading to educational and vocational competencies so that the individual will acquire necessary capacities for future adult independent living.
    explanation: >-
      Supports continued functional skill development.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Genetic counseling
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    Discuss the recessive pedigree, segregation testing and reproductive options using the familial
    molecular finding when clinically established. Interpretation should include the limited AHSG gene-disease
    evidence; identifying any pair of rare AHSG variants does not itself confirm the diagnosis.
  evidence:
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Genetic counseling not only provides accurate information on the prognosis of disorders and recurrence risks, but also helps in removing guilt and allaying ongoing recrimination in families.
    explanation: >-
      General genetic counseling recommendation applied to this rare recessive presentation.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
    explanation: >-
      Provides the relevant family segregation context.
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
- name: Scalp and eye protection for hair loss
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  description: >-
    Protect exposed scalp skin with a hat or appropriate sunscreen, and consider glasses or other protection
    when eyelashes or eyebrows are absent. These practical measures are extrapolated from dermatology
    guidance for alopecia areata; they address loss of hair protection and do not imply shared immune
    pathogenesis or efficacy of alopecia-areata drugs in APMR1.
  evidence:
  - reference: url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care
    reference_title: 'Hair loss types: Alopecia areata self-care'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Wear a wide-brimmed hat or wig when outdoors.
    explanation: >-
      General hair-loss protection guidance applied to exposed scalp skin.
    directness: INDIRECT
  - reference: url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care
    reference_title: 'Hair loss types: Alopecia areata self-care'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If you don’t cover your head, apply sunscreen to your scalp.
    explanation: >-
      Supports sun protection of a hairless scalp.
    directness: INDIRECT
  - reference: url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care
    reference_title: 'Hair loss types: Alopecia areata self-care'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Wear a hat, sweatband, or glasses.
    explanation: >-
      This recommendation occurs under eye protection after loss of eyelashes or eyebrows.
    directness: INDIRECT
- name: Family support and individualized behavioral care
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  description: >-
    Offer family support and address behavioral or mental-health needs when present. Changes in behavior
    should prompt assessment for treatable contributors rather than being automatically attributed to
    intellectual disability. The guidance is general to intellectual disability and does not establish
    a characteristic psychiatric phenotype in APMR1.
  evidence:
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Each family is unique therefore the family support programmes must be individualized to meet the needs of the family in the context of care-giving and disability impact.
    explanation: >-
      Supports individualized family services.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Any changes in behavior compared to previous period, dip in overall functioning, and changes in vegetative functioning should be carefully recorded in each visit.
    explanation: >-
      Supports review of new behavioral or functional changes.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
diagnosis:
- name: Clinical and developmental assessment
  description: >-
    Document the onset and distribution of alopecia together with intellectual and adaptive functioning,
    pedigree and other ectodermal or neurologic findings. Clinical overlap requires consideration of
    other inherited alopecia-intellectual disability syndromes.
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Directly documents the hair phenotype of the original linkage family.
  - reference: PMID:30745696
    reference_title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnostic process involves history taking, observation including medical examination, intellectual and adaptive behavioral assessment, identification of comorbid psychiatric disorders, and need-based laboratory investigations for other medical conditions.
    explanation: >-
      General ID assessment guidance; no APMR1-specific diagnostic score is established.
    directness: INDIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Molecular genetic evaluation
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Exome sequencing and family segregation analysis identified AHSG p.Arg317His in the reported family.
    In a new patient, assess the full clinical and genetic differential and interpret AHSG variants
    in light of the limited association evidence. The altered protein migration is a research finding
    rather than a validated standalone diagnostic assay.
  results: A compatible phenotype with a carefully interpreted familial AHSG finding may support APMR1; rare biallelic variants alone are insufficient.
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our study is the first report to identify a homozygous missense mutation for APMR syndrome through whole-exome sequencing.
    explanation: >-
      Describes the research identification method, not diagnostic sensitivity or universal confirmatory
      criteria.
    quote_role: PRIMARY_RESULT
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Previous families with APMR syndrome have been studied through linkage analyses and the linkage resolution did not allow pointing out to a single gene candidate.
    explanation: >-
      Explains why historical linkage families cannot automatically be treated as molecularly confirmed
      AHSG cases.
    quote_role: BACKGROUND
differential_diagnoses:
- name: Alopecia-Intellectual Disability Syndrome 4
  disease_term:
    preferred_term: alopecia-intellectual disability syndrome 4
    term:
      id: MONDO:0030009
      label: alopecia-intellectual disability syndrome 4
  description: >-
    LSS-related APMR4 shares congenital alopecia and intellectual disability. Developmental delay, epilepsy
    and additional findings occur in reported LSS cases; molecular testing distinguishes the conditions,
    while individual associated features are not absolute discriminators.
  evidence:
  - reference: PMID:38800572
    reference_title: Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is characterized by congenital alopecia and variable degrees of intellectual disability (ID), frequently associated with developmental delay (DD) and epilepsy.
    explanation: >-
      Describes the overlapping APMR4 spectrum.
    quote_role: BACKGROUND
  - reference: PMID:38800572
    reference_title: Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Two novel LSS variants (c.401 T > G and c.369C > G) were detected with whole-exome sequencing (WES).
    explanation: >-
      Supplies the different gene in the reported case.
- name: Atrichia with Papular Lesions
  disease_term:
    preferred_term: atrichia with papular lesions
    term:
      id: MONDO:0008847
      label: atrichia with papular lesions
  description: >-
    HR-related atrichia can cause extensive early hair loss. Hair loss soon after birth followed by
    a diffuse papular rash is a distinguishing pattern; evaluation of the cognitive phenotype and molecular
    findings is needed when APMR1 is considered.
  evidence:
  - reference: PMID:10504459
    reference_title: Atrichia with papular lesions resulting from a nonsense mutation within the human hairless gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Atrichia with papular lesions is a rare autosomal recessive form of alopecia characterized by hair loss soon after birth and the development during childhood of a diffuse papular rash.
    explanation: >-
      Supports the distinguishing timing and skin findings.
  - reference: PMID:10504459
    reference_title: Atrichia with papular lesions resulting from a nonsense mutation within the human hairless gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In this report, we describe a novel nonsense mutation in exon 4 of the human hairless gene in a consanguineous kindred affected with atrichia with papular lesions.
    explanation: >-
      Directly supports HR as the causal gene for this differential.
discussions:
- discussion_id: apmr1_ahsg_gene_validity
  prompt: Which functional change connects AHSG p.Arg317His to alopecia and intellectual disability?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic AHSG Missense Variant
  - genetic#AHSG
  rationale: >-
    The association is supported by one extensively segregating family, positional concordance and altered
    protein migration. The reviewed evidence does not determine whether the variant changes processing,
    ligand antagonism, cell migration or another function. ClinVar submissions and later reviews are
    not independent mechanistic replication. The historical linkage family was unresolved at gene level.
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we present whole-exome sequencing results of a large consanguineous family segregating APMR syndrome with seven affected family members.
    explanation: >-
      Defines the reported association.
    quote_role: PRIMARY_RESULT
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, the altered protein migrates with an aberrant size relative to healthy individuals.
    explanation: >-
      Defines the measured biochemical difference without assigning its mechanism.
    quote_role: PRIMARY_RESULT
- discussion_id: apmr1_ahsg_model_scope
  prompt: What do the AHSG-null observations establish about the APMR1 allele?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#AHSG
  - animal_models#Ahsg-null mouse
  rationale: >-
    Ahsg-null mice were assessed principally for calcification, not hair cycling or cognition. A separate
    nine-week-old infant with homozygous p.Lys2Ter and undetectable circulating fetuin-A had infantile
    cortical hyperostosis and was followed for one year. The authors explicitly described an association
    without experimental proof of ICH causation. Neither study provides dedicated negative hair or cognitive
    testing that rules out loss of function in APMR1 or establishes a neomorphic mechanism. Targeted
    allele-matched functional and developmental studies are needed.
  evidence:
  - reference: PMID:31288248
    reference_title: Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: After 1 year of follow-up, the patient was completely well with no bone deformity and/or elevated inflammatory markers.
    explanation: >-
      Defines the limited clinical follow-up; no formal normal cognition or alopecia exclusion follows
      from this statement.
  - reference: PMID:31288248
    reference_title: Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Our study has several limitations; we report only an association between fetuin-A deficiency and ICH phenotype, but no in vivo experiment was conducted in order to prove causation.
    explanation: >-
      The primary authors limit the disease-causation interpretation.
  - reference: PMID:31288248
    reference_title: Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: By enzyme-linked immunosorbent assay (ELISA), we show a complete deficiency of this protein in the patient's serum, compared to controls.
    explanation: >-
      Directly establishes absent circulating protein in this separate infant case.
  - reference: PMID:12897203
    reference_title: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Taken together, our data demonstrate a critical role of Ahsg as an inhibitor of unwanted mineralization
    explanation: >-
      Identifies what the mouse experiments establish.
- discussion_id: apmr1_developmental_routes
  prompt: Do fetuin-A expression and keratinocyte migration explain the congenital hair and cognitive findings?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Alopecia of Scalp
  - phenotypes#Intellectual Disability
  rationale: >-
    Normal fetal plasma/CSF concentrations and skin-cell migration effects support developmental plausibility,
    but neither demonstrates a necessary role in human neocortical development or follicular placode
    formation. The primary keratinocyte study examined newborn foreskin and adult skin, not human fetal
    placode development. Its primary-cell and HaCaT responses to EGFR blockade differ. These observations
    motivate alternatives to the hair-cycle hypothesis without establishing an APMR1-specific route.
  evidence:
  - reference: PMID:7680865
    reference_title: alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The concentration of alpha 2HS-glycoprotein (alpha 2HS), a human homologue of the fetal protein fetuin, has been measured in plasma and cerebrospinal fluid (CSF) of fetuses from 14 to 37 weeks of gestation and in cord blood from newborn babies.
    explanation: >-
      Primary developmental concentration study; expression is not causal evidence of neocortical
      malformation.
  - reference: PMID:7680865
    reference_title: alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The levels were highest in both plasma and CSF in the younger fetuses, but even in the newborn the concentration of alpha 2HS in plasma was nearly twice the adult level.
    explanation: >-
      Defines the observed age-related concentration pattern.
  - reference: PMID:19758338
    reference_title: 'Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In this study, we found that in human newborn foreskin, a high level of fetuin-A protein is detected throughout the dermis.
    explanation: >-
      Identifies the actual human tissue and stage studied.
  - reference: PMID:19758338
    reference_title: 'Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Fetuin-A significantly induces actin-rich protrusions in human primary keratinocytes.
    explanation: >-
      Provides a culture result rather than proof of placode formation.
- discussion_id: apmr1_locus_series_confusion
  prompt: Which gene or locus belongs to each numbered APMR form?
  kind: INTERPRETATION
  status: RESOLVED
  attaches_to:
  - disease#Alopecia-Intellectual Disability Syndrome 1
  rationale: >-
    APMR1 was mapped to 3q26.33-q27.3 and later associated with AHSG at 3q27.3. APMR2 is a non-overlapping
    chromosome 3 locus; APMR3 maps to chromosome 18; LSS-related APMR4 maps to chromosome 21. Findings
    from the different families require their own subtype and gene attribution.
  resolution_note: The entry retains APMR1 as a distinct disease and the existing APMR grouping. Unidentified genes do not prevent disease curation, and the numbered forms are not all on different chromosomes.
  evidence:
  - reference: PMID:16922726
    reference_title: A novel locus for alopecia with mental retardation syndrome (APMR2) maps to chromosome 3q26.2-q26.31.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The linkage interval of the APMR locus identified here does not overlap with the one described previously; therefore, this locus has been designated as APMR2.
    explanation: >-
      Separates the two chromosome 3 loci.
  - reference: PMID:33881165
    reference_title: 'Alopecia-mental retardation syndrome: Molecular genetics of a rare neuro-dermal disorder.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Among them, AHSG was reported in a consanguineous Iranian family and LSS gene in a Swiss origin family, while the remaining two uncharacterized loci, that is, APMR2 and APMR3, are reported in the Pakistani population.
    explanation: >-
      Review of the distinct gene/locus assignments.
    quote_role: REVIEW_SYNTHESIS
references:
- reference: PMID:10504459
  title: Atrichia with papular lesions resulting from a nonsense mutation within the human hairless gene.
- reference: PMID:12060393
  title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
- reference: PMID:12853704
  title: Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas.
  findings:
  - statement: Adult glioma CSF study; its fetal-neocortex statement is background, not primary developmental evidence for APMR1.
- reference: PMID:12897203
  title: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.
- reference: PMID:16273389
  title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
- reference: PMID:16922726
  title: A novel locus for alopecia with mental retardation syndrome (APMR2) maps to chromosome 3q26.2-q26.31.
- reference: PMID:17451405
  title: Mapping of a gene for alopecia with mental retardation syndrome (APMR3) on chromosome 18q11.2-q12.2.
  findings:
  - statement: Full APMR3 linkage report reviewed for locus separation; its four affected relatives are not the APMR1 clinical cohort.
- reference: PMID:19758338
  title: 'Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.'
- reference: PMID:28054173
  title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
- reference: PMID:30745696
  title: Clinical Practice Guidelines for Assessment and Management of intellectual disability.
- reference: PMID:31288248
  title: Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).
- reference: PMID:33881165
  title: 'Alopecia-mental retardation syndrome: Molecular genetics of a rare neuro-dermal disorder.'
- reference: PMID:38800572
  title: Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants.
- reference: PMID:7680865
  title: alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid.
- reference: PMID:8662721
  title: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
- reference: url:https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
  title: https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
- reference: url:https://www.aad.org/public/diseases/hair-loss/types/alopecia/self-care
  title: 'Hair loss types: Alopecia areata self-care'
- reference: url:https://www.ncbi.nlm.nih.gov/clinvar/RCV000578120/
  title: NM_001622.4(AHSG):c.950G>A (p.Arg317His) AND Alopecia-intellectual disability syndrome 1 - ClinVar - NCBI
notes: >-
  Disease-specific evidence remains concentrated in the original linkage family and the AHSG association
  family. General developmental and dermatologic care is explicitly extrapolated. No disease-specific
  therapeutic benefit is inferred from fetuin supplementation in normal follicle culture, and no population
  frequency is inferred from family ascertainment. The APMR group prevalence estimate is not an APMR1
  prevalence measurement.
progression:
- phase: Congenital hair phenotype and developmental assessment
  notes: >-
    Scalp hair was absent from birth in the original APMR1 linkage family. Intellectual disability was
    identified during clinical assessment. This report does not establish the onset or longitudinal
    course for all people with AHSG variants, and body sites that normally acquire hair at puberty require
    age-appropriate interpretation.
  evidence:
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In individuals affected with APMR syndrome, hairs were completely absent by birth from all areas of normal hair growth including scalp, eyebrows, eyelashes, axillary and pubic hair.
    explanation: >-
      Directly supports congenital scalp alopecia in the linkage family; it does not supply age-specific
      denominators for axillary or pubic hair.
  - reference: PMID:16273389
    reference_title: Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, all the affected individuals were similarly severely mentally retarded and were described as difficult to handle.
    explanation: >-
      Documents developmental impairment in the ascertained family without proving a progressive course.
biochemical:
- name: Altered fetuin-A electrophoretic migration
  presence: PRESENT
  notes: >-
    The p.Arg317His report observed altered AHSG protein size/migration in serum. This is a research
    observation, not a validated diagnostic biomarker or a measurement of reduced fetuin-A activity.
    Altered phosphorylation or processing was predicted; the migration shift alone does not establish
    its molecular explanation.
  evidence:
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, the altered protein migrates with an aberrant size relative to healthy individuals.
    explanation: >-
      Reports the observed protein migration difference.
    quote_role: PRIMARY_RESULT
  - reference: PMID:28054173
    reference_title: Association of AHSG with alopecia and mental retardation (APMR) syndrome.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: The variant is predicted to affect a region of the protein required for protein processing and disrupts a phosphorylation motif.
    explanation: >-
      The proposed processing/phosphorylation effect is a prediction.
    quote_role: PRIMARY_RESULT
experimental_models:
- name: Human hair follicle organ culture with TGF-beta2 and fetuin
  experimental_model_type: OTHER
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Human hair follicles; no APMR1 genotype tested
  description: >-
    TGF-beta2 suppressed hair elongation, while neutralizing antibody and fetuin promoted elongation
    in organ culture. This experiments with a candidate hair-cycle pathway but does not reproduce the
    APMR1 allele or congenital follicle development.
  publication: PMID:12060393
  modeled_mechanisms:
  - target: Premature Hair Follicle Catagen Entry
    relationship: PERTURBS
    fidelity: LOW
    model_scale: TISSUE
    description: Manipulates a ligand implicated in normal human catagen and measures hair elongation.
    limitations: The measured elongation response is not demonstration of premature catagen in APMR1 or rescue of a mutant follicle.
    evidence:
    - reference: PMID:12060393
      reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In the presence of the antibody as well as fetuin, hair follicles were markedly elongated in a concentration-dependent manner.
      explanation: >-
        Reports the experimental elongation response.
    - reference: PMID:12060393
      reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Elongation of hair was significantly suppressed by transforming growth factor-beta2.
      explanation: >-
        Reports the opposing ligand effect.
  evidence:
  - reference: PMID:12060393
    reference_title: Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: These results strongly suggest that transforming growth factor-beta2 plays an essential part in the induction of the catagen phase of the human hair cycle.
    explanation: >-
      Supports the hair-cycle context.
- name: Fetuin ligand binding and cytokine antagonism assays
  experimental_model_type: OTHER
  description: >-
    Surface plasmon resonance measured fetuin binding to TGF-beta and BMP ligands; competitive ELISA
    tested interference with TGF-beta1 receptor binding. These are biochemical experiments on fetuin
    function, without the APMR1 variant.
  publication: PMID:8662721
  evidence:
  - reference: PMID:8662721
    reference_title: Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Surface plasmon resonance measurements show that fetuin binds directly to TGF-beta1 and TGF-beta2 and with greater affinity to the TGF-beta-related bone morphogenetic proteins (BMP-2, BMP-4, and BMP-6).
    explanation: >-
      Direct biochemical binding measurements.
  notes: The results make altered ligand antagonism a testable candidate, but do not measure loss of antagonism by p.Arg317His.
- name: Primary human keratinocyte and HaCaT migration cultures
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Primary human keratinocytes and parallel immortalized HaCaT cultures
  description: >-
    Fetuin-A induced actin-rich protrusions and promoted wound closure. EGF receptor blockade had limited
    effects on the primary-cell response but substantially inhibited the HaCaT response. This provides
    an alternative cell-migration rationale outside APMR1, not evidence of impaired placode formation
    or mutant rescue.
  publication: PMID:19758338
  evidence:
  - reference: PMID:19758338
    reference_title: 'Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Fetuin-A significantly induces actin-rich protrusions in human primary keratinocytes.
    explanation: >-
      Documents the primary-cell morphology response.
  - reference: PMID:19758338
    reference_title: 'Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Interestingly, blockade of epidermal growth factor (EGF) receptor signalling has a limited effect on fetuin-A promoted 'wound closure' on primary human keratinocytes, but significantly inhibits fetuin-A's effect on HaCaT cells.
    explanation: >-
      Separates primary-cell and immortalized-cell signaling results.
📚

References & Deep Research

References

18
PMID:10504459
Atrichia with papular lesions resulting from a nonsense mutation within the human hairless gene.
No top-level findings curated for this source.
PMID:12060393
Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle.
No top-level findings curated for this source.
PMID:12853704
Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas.
1 finding
Adult glioma CSF study; its fetal-neocortex statement is background, not primary developmental evidence for APMR1.
PMID:12897203
The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.
No top-level findings curated for this source.
PMID:16273389
Localization of a novel locus for alopecia with mental retardation syndrome to chromosome 3q26.33-q27.3.
No top-level findings curated for this source.
PMID:16922726
A novel locus for alopecia with mental retardation syndrome (APMR2) maps to chromosome 3q26.2-q26.31.
No top-level findings curated for this source.
PMID:17451405
Mapping of a gene for alopecia with mental retardation syndrome (APMR3) on chromosome 18q11.2-q12.2.
1 finding
Full APMR3 linkage report reviewed for locus separation; its four affected relatives are not the APMR1 clinical cohort.
PMID:19758338
Fetuin-A promotes primary keratinocyte migration: independent of epidermal growth factor receptor signalling.
No top-level findings curated for this source.
PMID:28054173
Association of AHSG with alopecia and mental retardation (APMR) syndrome.
No top-level findings curated for this source.
PMID:30745696
Clinical Practice Guidelines for Assessment and Management of intellectual disability.
No top-level findings curated for this source.
PMID:31288248
Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).
No top-level findings curated for this source.
PMID:33881165
Alopecia-mental retardation syndrome: Molecular genetics of a rare neuro-dermal disorder.
No top-level findings curated for this source.
PMID:38800572
Clinical and genetic analyses of APMR4 syndrome caused by novel biallelic LSS variants.
No top-level findings curated for this source.
PMID:7680865
alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid.
No top-level findings curated for this source.
PMID:8662721
Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.
No top-level findings curated for this source.
url:https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
https://artefacts-discovery.researcher.life/full_text/DA-2/b2/b2fe4e2735e33626a9c05554fa7359f5/full_text/5addfdec534c3e45bdc76a440a5cc24f.pdf
No top-level findings curated for this source.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/clinvar/RCV000578120/
NM_001622.4(AHSG):c.950G>A (p.Arg317His) AND Alopecia-intellectual disability syndrome 1 - ClinVar - NCBI
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Review APMR1 clinical and mechanistic evidence · 2026-09-21T07:44:47Z · View source

Comprehensive review of all baseline references and available full texts, matching deep research, and GeneReviews baseline. Recovered the full original linkage report and AHSG-null infant report; used full APMR review and general ID guidance. Separated linkage-family clinical findings from AHSG association; removed unsupported prevalence and obligatory frequency bands; distinguished protein migration from predicted function; retained an explicitly optional hair-cycle hypothesis without an unsupported neurocortical causal chain. Corrected false negative interpretations of untested hair/cognition in null models and the infant follow-up. Added scoped experimental models, evidence-backed general supportive care, differential evidence and cautious molecular interpretation. Authoritative schema/live terms and all 72 evidence snippets pass. All 25 repository quality gates pass, including the corrected minimum-length ClinVar quotation; node-class validation resolves 101 classes and 2192 examples. Independent bounded audits checked the graph/null-model interpretation and clinical/genetic/care scope. The primary 2017 AHSG paper remains abstract-only after attempted full-text recovery; the available 2021 review supplies the table IQ summary, with that secondary scope stated. No dedicated GeneReviews or StatPearls chapter exists. All reference caches were generated with just fetch-reference; failed CAPTCHA content was excluded.

Create: Alopecia-Intellectual Disability Syndrome 1 (APMR1, AHSG) · 2026-08-26T09:10:53Z · View source

Curated APMR1 (MONDO:0021035, AHSG / fetuin-A) de novo, using Edison (falcon) deep research on Alopecia-Intellectual_Disability_Syndrome_1 (613 s, 19 citations). Scope decision. Issue #8364 targeted the APMR root MONDO:0008756 as CURATE_ROOT_WITH_SUBTYPES. That was not followed literally: the four numbered APMR forms have different causal genes on different chromosomes, so has_subtypes would assert a single-gene severity spectrum that does not exist. The root is modelled as kb/groupings/Alopecia-Intellectual_Disability_Syndromes.yaml over APMR1 and APMR4, which is what the existing APMR4 entry's own modelling note asked for once a second member existed. APMR1 is that member. The issue body's gene hints (APMR1 = LSS/HR locus, APMR3 = LSS) are wrong and were not used; the primary-source trace is recorded in the apmr1_locus_series_confusion discussion. NEC preflight. just preflight-dr returned SKIP because MONDO records no RO:0004003 causal gene for MONDO:0021035, so the gene-identity check could not discriminate. Fell back to the manual OMIM/synonym check: the report's gene frequencies are AHSG=28 vs LSS=3, and OMIM 203650 matches the intended entity. No NEC failure. Note that the report's frontmatter records confabulation_rate 0.5, but all three unresolved references are the same extractor bug (a markdown link swallowed into the DOI, e.g. DOI:10.1007/s00439-016-1756-5](https://doi.org/...); all three DOIs resolve normally. What Edison added beyond the issue's research comment: the Demetriou 1996 TGF-beta/BMP type-II-receptor-mimic mechanism (PMID:8662721), and, decisively, that a homozygous AHSG nonsense allele with ELISA-confirmed complete fetuin-A deficiency causes Caffey disease rather than APMR1 (PMID:31288248). The latter is curated as the strongest constraint on the mechanism model: a human AHSG null gives a skeletal phenotype, so the APMR1 missense is unlikely to act by simple absence of protein. Evidence discipline. The gene-disease assertion rests on one consanguineous family, one predicted-pathogenic missense, and no functional rescue, so the trigger node is mechanism_confidence PROVISIONAL, the variant is LIKELY_PATHOGENIC rather than PATHOGENIC, and every node downstream is HYPOTHETICAL under the EMERGING fetuin_tgfb_antagonism_model hypothesis group. Two open discussions record the gene-validity gap and the human/mouse null mismatch, with two proposed experiments. One evidence item was dropped rather than quoted around a PDF hyphenation defect in the cached full text of PMID:17451405 (chromo-some). Validation: just validate, just validate-disorders, count-verified-snippets (42/42 for the disorder, 8/8 for the grouping), check-entity-refs, check-duplicate-keys, check-folded-hyphens, check-snippet-length, check-title-snippets, check-environmental-evidence, validate-grouping, check-groupings (both members SATISFIED), and pytest -k "entity_ref or grouping or subtype or model_readout or failure_to_recapitulate" (14831 passed). Review round 1 (ai4c-reviewer, request changes). Two blocking content gaps, both closed: (a) hair phenotypes were folded into one generic Alopecia node, so the scalp node was rebound to HP:0002293 and separate Absent Eyebrow (HP:0002223), Absent Eyelashes (HP:0000561), Absent Axillary Hair (HP:0002221) and Absent Pubic Hair (HP:0002555) entries were added off the PMID:17451405 snippet already in the file; (b) treatments: and diagnosis: were absent with no recorded reason, so supportive care, genetic counselling and the molecular-testing route were added. Note two deliberate divergences from the sibling APMR4 entry, both recorded in the file: the absent- rather than sparse- hair terms are bound because the APMR sources describe absence, and no onset descriptor is asserted because no APMR1 report gives an age at onset. Serum fetuin-A electrophoresis was deliberately not promoted to diagnosis: as it is a single research observation with no validated assay characteristics. Non-blocking suggestions also taken: the primary authors' own keratinocyte-migration and follicular-placode route is now named in the hypothesis description as an unmodelled competitor (its evidence is full-text-only and so unquotable), the dbSNP rsID was added, the Caffey MONDO binding caveat was recorded, the mild-to- moderate ID claim is now attributed to PMID:38800572, the IQ 40-54 figure is recorded with deep-research provenance, and three unreferenced duplicate DOI cache files were removed. Renaming the Alopecia phenotype node required repointing the causal edge that targeted it; check-entity-refs does not catch that class of dangling reference because plain target: values carry no # anchor. Scope note. The grouping's CURATION_TODO discussion initially carried attaches_to: [members#], which needed a members prefix added to entity_refs.SECTION_KEYS - that map covers Disease sections only, so entity references in kb/groupings have no resolvable anchor. CI's curation-scope guard correctly rejected src/ and tests/ changes in a kb/ PR, so the source change was reverted and the anchor dropped from the discussion. The SECTION_KEYS gap is reported as a separate infrastructure issue rather than folded into this curation PR or waved through with a scope-override label.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 19 citations 2026-08-26T08:48:51.216269

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Alopecia-Intellectual Disability Syndrome 1
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Alopecia-Intellectual Disability Syndrome 1 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Alopecia–Intellectual Disability Syndrome 1 (APMR1): comprehensive disease-characteristics report

Executive summary and evidence limits

Alopecia–intellectual disability syndrome 1 (APMR1; historically alopecia–mental retardation syndrome 1) is an exceptionally rare autosomal-recessive neurocutaneous disorder characterized principally by partial or complete alopecia and intellectual disability. The molecular evidence currently rests mainly on one large consanguineous Iranian family: seven affected relatives were homozygous for AHSG c.950G>A (p.Arg317His; rs201849460), whereas seven unaffected relatives carried either one variant allele or the reference genotype. The association is compelling but not yet supported by numerous unrelated families or a disease-recapitulating experimental model. Accordingly, AHSG should be treated as the reported/proposed APMR1 causal gene, with limited replication, rather than as a comprehensively validated gene–disease relationship. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 3-4)

The most important recent disease-family update is a 2024 comparative APMR study. It continues to distinguish APMR1 from LSS-related APMR4 and describes APMR1 as generally involving mild-to-moderate intellectual disability; however, it adds little new APMR1-specific molecular evidence. (kang2024clinicalandgenetic pages 1-2)

Domain Key findings Quantitative details Evidence level Citation
Identity / identifier Disease resolved as alopecia-mental retardation syndrome 1 (APMR1), a very rare autosomal recessive condition mapped to chromosome 3q26.33-q27.3; characterized by alopecia with intellectual disability. OMIM given as 203650. Single disease entity discussed in one primary molecular report; linkage region reported as 17 Mb on chr3. Human clinical / gene-mapping (sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 4-7)
Gene and variant Candidate causal gene is AHSG (alpha-2-HS-glycoprotein; fetuin-A; OMIM 138680). Reported disease-associated variant: c.950G>A (p.Arg317His) in exon 7; dbSNP rs201849460. Variant genomic position reported as chr3:186338565; rarity in ExAC reported as MAF 0.0008%. In silico scores: MutationTaster 0.95, PolyPhen 0.99, SIFT 0.0. Human segregation + computational (sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 3-4)
Inheritance / family Inheritance is consistent with autosomal recessive transmission in a large consanguineous Iranian family. Variant segregated with disease. 7 affected homozygous individuals; 7 unaffected relatives were heterozygous or homozygous reference; segregation significance reported as chi-square P=0.01. Human segregation (sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 3-4)
Phenotype and patient counts Core phenotype is alopecia plus intellectual disability. Hair loss may be complete or partial. APMR1 is described in 2024 context as having mild-to-moderate ID; developmental delay and epilepsy have been noted in APMR1 generally, but were not individually detailed in the extracted 2017 family table. 7 affected relatives total; ages explicitly visible for 7 individuals: 3Y, 4Y, 14Y, 17Y, 21Y, 23Y, 24Y; sexes: 4 male, 3 female; alopecia pattern among listed individuals: 3 complete, 4 partial; IQ range 40-54. Human clinical observation (sailani2017associationofahsg pages 3-4, kang2024clinicalandgenetic pages 1-2)
Functional evidence AHSG/fetuin-A is implicated in protein processing/post-translational modification, BMP/TGF-beta antagonism, keratinocyte migration, and possible brain developmental roles. The APMR1 variant lies in the protein processing region and is predicted to disrupt a phosphorylation motif near Thr319; patient serum AHSG showed altered migration on SDS-PAGE. Predicted loss/change of kinase recognition around p.Thr319 with probabilities reported in one analysis as 0.96-0.74 for PKA/DMPK/AUR kinases; western blot showed two bands in affected versus single bands in unaffected controls. In vitro / biochemical + computational (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 3-4, sailani2017associationofahsg pages 7-8, sailani2017associationofahsg pages 8-9)
Diagnosis No disease-specific standardized diagnostic criteria were identified. Current practical diagnosis depends on recognizing the phenotype and confirming biallelic AHSG variation, typically via whole-exome sequencing or other molecular testing. Broader ichthyosis/alopecia-neurodevelopmental literature supports NGS for rare syndromic differential diagnosis. In a syndromic/non-syndromic ichthyosis cohort, NGS achieved a molecular diagnosis in 53/64 patients (82.8%), illustrating utility of panel/WES approaches for overlapping phenotypes. Human diagnostic practice / extrapolated rare-disease genomics (sailani2017associationofahsg pages 1-3, kang2024clinicalandgenetic pages 1-2)
Treatment / trials No disease-specific therapy or management guideline for APMR1 was found in the retrieved evidence. Management is therefore presumed supportive and multidisciplinary (developmental, neurologic, dermatologic, rehabilitation, genetic counseling) rather than disease-modifying. No relevant interventional clinical trials were retrieved. 0 relevant trials found in the searched trial results. Evidence gap / no active trial evidence retrieved (sailani2017associationofahsg pages 3-4)
Major evidence gaps Evidence base is extremely limited: one genetically resolved family, sparse natural-history data, no prevalence/incidence estimates, no penetrance estimates, no standardized diagnostic criteria, no biomarker validation, no disease-specific therapy, and no direct APMR1 animal model identified. Existing animal evidence for AHSG is indirect and comes from other phenotypes involving fetuin-A deficiency. Human molecular evidence currently rests mainly on 1 family / 7 affected individuals; indirect AHSG biology from knockout animals links fetuin-A deficiency to mineralization and bone phenotypes rather than a fully recapitulated APMR1 syndrome. Animal indirect + evidence gap (sailani2017associationofahsg pages 1-3, merdlerrabinowicz2019fetuinadeficiencyis pages 3-4, merdlerrabinowicz2019fetuinadeficiencyis pages 4-5)

Table: This table summarizes the strongest currently available evidence for alopecia-mental retardation syndrome 1 (APMR1), including identifiers, AHSG variant data, family segregation, phenotype counts, functional findings, and the major unresolved gaps. It is useful for rapidly distinguishing established human evidence from indirect mechanistic or animal evidence.

1. Disease information

Definition and identifiers

  • Preferred name: Alopecia–intellectual disability syndrome 1.
  • Historical names/synonyms: alopecia–mental retardation syndrome 1; APMR1; alopecia with mental retardation syndrome; AHSG-associated alopecia–intellectual disability syndrome.
  • OMIM phenotype: 203650.
  • Mapped locus: chromosome 3q26.33–q27.3, originally a roughly 17-Mb linkage interval.
  • Gene entry: AHSG, OMIM 138680; protein alpha-2-HS-glycoprotein/fetuin-A.
  • MONDO, Orphanet, MeSH, ICD-10 and ICD-11: a disease-specific identifier/code was not established in the retrieved evidence. For coding, a combination of alopecia, intellectual disability, and genetic-syndrome categories may be necessary; these are not equivalent to a dedicated APMR1 code and should not be entered as exact mappings.
  • Category: Mendelian, autosomal recessive, neurocutaneous/neuroectodermal syndrome. (sailani2017associationofahsg pages 1-3)

The evidence is aggregated family-level research data, not EHR-derived population data. Individual-level details were reported for seven affected relatives, but no registry or population cohort exists in the retrieved literature. (sailani2017associationofahsg pages 3-4)

Primary source: Sailani et al., Human Genetics, published January 2017, DOI 10.1007/s00439-016-1756-5. A PMID was not available in the retrieved record and should be verified directly in PubMed before database deposition. (sailani2017associationofahsg pages 1-3)

2. Etiology

Causal and genetic factors

The reported molecular cause is homozygosity for AHSG c.950G>A, p.Arg317His, an exon-7 missense variant. It lay both within the prior linkage interval and a run of homozygosity, segregated with disease, and was extremely rare in ExAC (MAF 0.0008%). Reported predictions were MutationTaster 0.95, PolyPhen 0.99, and SIFT 0.0. The variant affects a conserved residue in a protein-processing region. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 1-3)

The variant was homozygous in all seven affected relatives. Seven unaffected relatives were heterozygous or reference homozygotes; reported segregation was χ² P=0.01. This supports recessive inheritance, but one pedigree cannot establish population-wide penetrance or the full allelic spectrum. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 3-4)

Other risk, protective, and gene–environment factors

  • Established risk: biallelic inheritance of the familial AHSG allele; parental consanguinity increases the probability that descendants inherit the same rare allele from both parents.
  • Environmental or infectious risk factors: none demonstrated.
  • Lifestyle risks: none demonstrated.
  • Protective alleles, modifier genes, or protective exposures: none reported.
  • Gene–environment interaction: not studied.
  • Somatic contribution: unsupported; this is presumed a germline disorder.

These absences reflect lack of evidence, not proof that modifiers cannot exist.

3. Phenotypes

Core observed phenotype

All seven molecularly described relatives had alopecia and intellectual disability. Ages were 3, 4, 14, 17, 21, 23, and 24 years; there were four males and three females. Three were described as having complete alopecia and four partial alopecia. All had reported Stanford–Binet IQ values in the 40–54 range. Thus, within this selected family, both major manifestations occurred in 7/7 (100%), although this cannot be generalized to all future AHSG genotypes. (sailani2017associationofahsg pages 7-8, sailani2017associationofahsg pages 3-4)

The disease-level description includes loss of scalp hair and absence of eyebrows and eyelashes. Recent comparative literature classifies APMR1 intellectual disability as usually mild-to-moderate and states that developmental delay and epilepsy can occur in APMR1, but the retrieved primary family text did not provide patient-by-patient seizure histories, onset ages, EEG results, or developmental milestones. (sailani2017associationofahsg pages 1-3, kang2024clinicalandgenetic pages 1-2)

Ontology-ready phenotype suggestions

Manifestation Type/course Suggested HPO annotation
Partial or complete scalp alopecia Physical sign; pediatric presentation documented; persistence likely, but formal longitudinal data absent Alopecia (HP:0001596); consider partial/total alopecia child terms after HPO verification
Absent/sparse eyebrows Physical sign; disease-level description Sparse eyebrow (HP:0045075) or absent eyebrow term after ontology verification
Absent/sparse eyelashes Physical sign Sparse eyelashes (HP:0000653) or absent eyelashes term after verification
Intellectual disability, IQ 40–54 Neurodevelopmental/behavioral phenotype; mild-to-moderate in recent comparison Intellectual disability (HP:0001249); moderate ID HP:0002342 where supported individually
Developmental delay Reported at syndrome-comparison level, not quantified in the foundational family Global developmental delay (HP:0001263)
Epilepsy/seizures Reported as possible in APMR1 comparison; individual frequencies unavailable Seizure (HP:0001250) / Epilepsy (HP:0001250 family of terms)

Quality of life

No EQ-5D, SF-36, PROMIS, caregiver-burden, educational-attainment, or adaptive-function data exist in the retrieved literature. Intellectual disability is expected to affect learning and independent function; alopecia may affect appearance and psychosocial well-being, but APMR1-specific quantitative effects have not been measured.

4. Genetic and molecular information

Gene and variant annotation

  • Gene: AHSG (alpha-2-HS-glycoprotein), encoding secreted fetuin-A.
  • Variant: c.950G>A (p.Arg317His); exon 7; rs201849460; reported genomic coordinate chr3:186338565 in the source assembly.
  • Variant class: missense, germline, homozygous in affected relatives.
  • Population frequency: ExAC MAF 0.0008% in the 2017 report; current gnomAD frequency and ancestry-specific counts require direct contemporary database verification.
  • ClinVar/ACMG status: no current ClinVar assertion was established from retrieved evidence. “Pathogenic” should not be imported solely from prediction scores; a contemporary ACMG/AMP assessment should incorporate segregation, rarity, phenotype specificity, functional data, and any newer submissions.
  • Functional direction: probably altered protein maturation/post-translational regulation rather than complete null function. The exact mechanism—loss of function, hypomorph, neomorph, or altered phosphorylation—remains unresolved. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 3-4)

No APMR1-associated copy-number variant, translocation, repeat expansion, mitochondrial variant, modifier gene, methylation signature, or other epigenetic abnormality has been reported.

5. Environmental information

No toxins, radiation, pollution, occupation, diet, smoking, alcohol, physical activity, medication, or infectious agent has been causally associated with APMR1. Because the disorder segregates as a rare Mendelian trait, environmental exposure is not considered the primary cause. Environmental influences on hair retention, seizures, cognition, or AHSG biology have not been tested specifically in affected people.

6. Mechanism and pathophysiology

Normal protein biology

Fetuin-A is an approximately 52-kDa, negatively charged, secreted glycoprotein produced principally by hepatocytes. It is also produced by osteocytes and, to a lesser extent, osteoblasts. It binds calcium phosphate, forms soluble protein–mineral complexes, and inhibits ectopic calcification. Fetuin-A can mimic a TGF-β type-II receptor and antagonize TGF-β/BMP-family ligands, with reported binding to TGF-β1/2 and BMP-2, BMP-4, and BMP-6. (merdlerrabinowicz2019fetuinadeficiencyis pages 3-4, merdlerrabinowicz2019fetuinadeficiencyis pages 5-5)

Relevant to APMR1, AHSG is strongly expressed during development: the protein has high fetal plasma and CSF concentrations, is synthesized by early developing neurons in immature neocortex, and is expressed in developing hair follicles where basal keratinocytes reorganize into follicular placodes. The 2017 work also reported promotion of primary keratinocyte migration and greater expression in fetal than postnatal skin. These observations provide biological plausibility for combined hair and neurodevelopmental phenotypes. (sailani2017associationofahsg pages 7-8, sailani2017associationofahsg pages 8-9)

Proposed causal chain

  1. Upstream genetic event: homozygous AHSG p.Arg317His.
  2. Molecular consequence: disruption of a recognition motif near Thr319; computational analyses predicted altered PKA/DMPK/AUR-family kinase recognition, with reported probabilities around 0.74–0.96.
  3. Protein consequence: altered maturation or post-translational modification. Patient-serum Western blot showed two AHSG bands in affected people versus a single band in unaffected controls.
  4. Cellular/tissue consequences, still hypothetical: disturbed fetuin-A signaling or extracellular availability may impair keratinocyte migration/hair-follicle placode development and alter developmental BMP/TGF-β regulation in the immature neocortex.
  5. Clinical outcome: alopecia plus intellectual/developmental impairment, with possible epilepsy. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 3-4)

Steps 1 and segregation are human genetic observations; step 3 is human biochemical evidence; the links from altered bands/phosphorylation to follicular and neural dysfunction remain mechanistic hypotheses rather than demonstrated causal experiments.

Suggested ontology annotations

  • GO biological processes: protein phosphorylation (GO:0006468), protein processing (GO:0016485), BMP signaling pathway (GO:0030509), TGF-β receptor signaling (GO:0007179), keratinocyte migration, hair-follicle development (GO:0001942), nervous-system development (GO:0007399), biomineralization (GO:0110148).
  • GO cellular components: extracellular region (GO:0005576), extracellular space (GO:0005615), blood microparticle/serum-associated compartment where appropriate.
  • Cell Ontology candidates: hepatocyte (CL:0000182), keratinocyte (CL:0000312), neuron (CL:0000540), osteocyte (CL:0000137), osteoblast (CL:0000062). Hair-follicle placode/basal keratinocyte terms should be checked against the current CL release.

Immune, metabolic, and omics evidence

There is no demonstrated autoimmune alopecia, immunodeficiency, chronic inflammation, specific metabolomic signature, lipidomic profile, transcriptomic signature, proteomic panel, single-cell dataset, spatial-transcriptomic study, multi-omics integration, or CRISPR/RNAi screen for APMR1. Fetuin-A’s mineral metabolism functions are established generally, but no mineral or skeletal abnormality was quantified in the APMR1 family.

7. Anatomical structures affected

The directly observed organ systems are:

  • Integumentary: scalp hair follicles; eyebrows and eyelashes. Suggested UBERON terms include hair follicle (UBERON:0002073), scalp, eyebrow, and eyelash structures after current-release verification.
  • Nervous system: developmental brain/cognitive function; the neocortex is biologically plausible from fetal AHSG localization, but no APMR1-specific neuropathology or imaging lesion was established. Suggested terms: brain (UBERON:0000955) and cerebral cortex (UBERON:0000956).
  • Cell/tissue: follicular keratinocytes and developing neurons are candidate affected populations.
  • Subcellular level: the evidence points to a secreted extracellular protein and altered post-translational processing; no disease-specific organelle lesion is known. (sailani2017associationofahsg pages 7-8, sailani2017associationofahsg pages 8-9)

Alopecia is not described as unilateral; involvement appears generalized/bilateral. Formal lateralization data are absent.

8. Temporal development

Affected children were documented as young as age 3, supporting early childhood expression. The disease is frequently described within the broader APMR family as congenital or early-onset alopecia, but exact onset dates were not available for the APMR1 relatives. Intellectual impairment is developmental rather than an adult neurodegenerative presentation. (sailani2017associationofahsg pages 3-4)

No validated disease stages, progression rate, remission pattern, critical therapeutic window, or longitudinal natural-history series exists. Persistence into ages 21–24 indicates a chronic/lifelong phenotype, but whether partial alopecia predictably progresses to complete alopecia is unproven.

9. Inheritance and population

  • Inheritance: autosomal recessive.
  • Pedigree: consanguineous Iranian family.
  • Observed sex distribution: 4 male and 3 female affected relatives, consistent with an autosomal condition but too small for a meaningful sex ratio.
  • Penetrance: appeared complete among seven homozygotes in this family; population-level penetrance is unknown.
  • Expressivity: variable alopecia severity—3/7 complete and 4/7 partial—despite the same familial genotype.
  • Anticipation: not reported and not mechanistically expected for a missense allele.
  • Germline mosaicism: not reported.
  • Founder effect: not established beyond one consanguineous kindred.
  • Carrier frequency: unknown.
  • Prevalence/incidence: no reliable cases-per-100,000 estimate. The evidence base of one molecularly resolved family implies an ultra-rare disorder but does not permit a numerical prevalence calculation. (sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 3-4)

10. Diagnostics

Recommended practical workflow

  1. Clinical assessment: document distribution and onset of scalp/eyebrow/eyelash alopecia; complete dermatologic and hair-shaft examination; developmental, neurologic, seizure, hearing, vision, growth, and dysmorphology assessment.
  2. Phenotyping: standardized cognitive/developmental testing and three-generation pedigree, including consanguinity.
  3. Genomic testing: a neurodevelopmental-disorder/alopecia panel that includes AHSG, or preferably trio/parent–child WES because of extensive differential diagnosis. Confirm candidate variants by Sanger sequencing and segregation analysis.
  4. If sequencing is negative: CNV-aware exome analysis or genome sequencing; CMA is appropriate when syndromic intellectual disability suggests a chromosomal imbalance. Karyotype/FISH are not first-line for this single-nucleotide disorder unless cytogenetic findings are suspected.
  5. Variant interpretation: verify transcript, phase, population frequency in current gnomAD, ClinVar assertions, and phenotype concordance. Functional serum fetuin-A electrophoresis is research-level, not a validated clinical diagnostic assay. (sailani2017associationofahsg pages 1-3, sailani2017associationofahsg pages 3-4)

No validated blood biomarker, enzyme assay, imaging pattern, EEG signature, biopsy criterion, prenatal ultrasound sign, or formal diagnostic score exists.

Differential diagnosis

Important genetic alternatives include APMR2, APMR3, and LSS-related APMR4; IFAP/BRESHECK syndrome; Menkes disease; Woodhouse–Sakati syndrome; Coffin–Siris spectrum; ectodermal dysplasias; and other syndromic alopecias/neurodevelopmental disorders. APMR4 can include congenital alopecia, variable ID, developmental delay, and epilepsy and is caused by biallelic LSS variants. Recent comparison reports mild-to-moderate ID in APMR1/2, severe ID in APMR3, and mild-to-severe ID in APMR4. (kang2024clinicalandgenetic pages 1-2)

Molecular testing is particularly important because phenotype overlap is substantial. In a broader 64-person ichthyosis cohort—not an APMR1 cohort—NGS identified pathogenic variants in 53 patients (82.8%), illustrating the diagnostic value of broad sequencing but not an APMR1-specific sensitivity.

Screening

No population or newborn screening is indicated. Once a familial pathogenic/likely pathogenic genotype is confirmed, targeted cascade carrier testing, prenatal diagnosis, and preimplantation genetic testing are technically feasible. These require genetic counseling and careful acknowledgment that the AHSG–APMR1 relationship has limited independent replication.

11. Outcome and prognosis

No survival curves, mortality rate, life-expectancy estimate, hospitalization rate, or prognostic biomarker has been published. Survival into the mid-20s was documented in the family, and there is no evidence that alopecia itself is life limiting. The principal known morbidity is neurodevelopmental disability, with potential seizure-related morbidity where epilepsy occurs. (sailani2017associationofahsg pages 3-4)

Recovery of established intellectual disability or spontaneous durable hair regrowth has not been documented. No quantitative adaptive-function or quality-of-life outcome is available. Prognostic correlations with alopecia extent, IQ, serum fetuin-A, or genotype are unknown.

12. Treatment and real-world implementation

There is no approved disease-modifying pharmacotherapy, gene therapy, RNA therapy, cell therapy, surgery, or genotype-guided drug regimen for APMR1. No relevant interventional trial was retrieved from ClinicalTrials.gov searches.

Current real-world management is therefore individualized and supportive:

  • early developmental intervention and special education;
  • speech/language, occupational, and physical therapy according to functional need;
  • neurology assessment and standard antiseizure treatment if epilepsy is confirmed;
  • dermatology evaluation, scalp care, cosmetic camouflage, wigs/prostheses, and psychological support;
  • periodic hearing, vision, growth, nutrition, and behavioral assessment based on clinical findings;
  • genetic counseling and family cascade testing.

Suggested NCIt intervention concepts include Genetic Counseling, Occupational Therapy, Physical Therapy, Speech and Language Therapy, Supportive Care, and Anticonvulsant Therapy; exact NCIt codes should be resolved against the current thesaurus. There are no APMR1-specific response rates, adverse-event datasets, pharmacogenomic recommendations, or treatment algorithms.

13. Prevention

The phenotype cannot currently be prevented after an affected genotype is established. Primary prevention is reproductive rather than environmental: carrier identification in the family, informed partner testing, prenatal diagnosis, or preimplantation genetic testing. Secondary prevention consists of early recognition of developmental delay or seizures and prompt intervention. Tertiary prevention includes educational/rehabilitative services, seizure control, psychosocial support, and surveillance tailored to identified complications.

Vaccination, infection prophylaxis, diet, exercise, toxin avoidance, or public-health environmental measures have no disease-specific preventive role beyond standard care.

14. Other species and natural disease

No naturally occurring veterinary counterpart of AHSG-associated APMR1 was identified; no breed association, zoonotic transmission, or cross-species infectious susceptibility applies. AHSG/fetuin-A is evolutionarily conserved, permitting comparative functional study, but conservation alone does not establish an animal disease homolog.

A separate human phenotype—infantile cortical hyperostosis—has been associated with a homozygous AHSG nonsense allele and complete fetuin-A deficiency. This demonstrates allelic/functional relevance of AHSG but should not be merged with APMR1 because its reported phenotype and molecular consequence differ. (merdlerrabinowicz2019fetuinadeficiencyis pages 3-4, merdlerrabinowicz2019fetuinadeficiencyis pages 4-5)

15. Model organisms

Available evidence

Ahsg-null mice are an indirect mechanistic model, not a validated APMR1 model. Reported phenotypes include severe extra-osseous renal calcification, accelerated growth-plate mineralization, increased femoral cortical thickness, a greater than twofold increase in cortical-to-cancellous bone ratio, immature bone islands, growth-plate defects, and shortened proximal limb bones. These findings support fetuin-A’s role in mineral chaperoning and BMP/TGF-β-regulated osteogenesis but do not reproduce the defining human alopecia–intellectual-disability combination. (merdlerrabinowicz2019fetuinadeficiencyis pages 3-4, merdlerrabinowicz2019fetuinadeficiencyis pages 5-5)

No p.Arg317His knock-in mouse, zebrafish, Drosophila, C. elegans, patient-derived iPSC, neural organoid, hair-follicle organoid, or humanized model was identified. The most informative future model would be a homozygous p.Arg317His knock-in system coupled with fetal cortical-neuron and hair-follicle-placode assays; key readouts should include fetuin-A processing/phosphorylation, secretion, BMP/TGF-β signaling, keratinocyte migration, folliculogenesis, neurodevelopment, cognition, and seizure susceptibility.

Expert assessment and research priorities

The strongest evidence is the internally consistent combination of linkage, homozygosity, rarity, segregation in 14 relatives, evolutionary conservation, and altered patient-protein electrophoretic behavior. Nevertheless, the absence of unrelated replicated families and direct variant-specific disease models limits certainty. The altered Western-blot migration shows a biochemical effect but does not prove that loss of Thr319 phosphorylation causes alopecia or intellectual disability. (sailani2017associationofahsg pages 4-7, sailani2017associationofahsg pages 3-4)

Priorities are: (1) identify independent biallelic AHSG cases through GeneMatcher/rare-disease genome programs; (2) perform formal ClinGen gene–disease curation; (3) measure secretion, glycosylation, phosphorylation, BMP/TGF-β antagonism, and migration in variant-engineered keratinocytes and neurons; (4) develop knock-in or patient-derived organoid models; and (5) establish prospective natural-history and patient-reported-outcome data.

Source and quotation note

The key primary report is Sailani et al., published January 2017: https://doi.org/10.1007/s00439-016-1756-5. The recent comparative source is Kang et al., published May 2024: https://doi.org/10.3389/fnins.2024.1301865. The indirect fetuin-A-deficiency/model source is Merdler-Rabinowicz et al., published July 2019: https://doi.org/10.1038/s41390-019-0499-0. (sailani2017associationofahsg pages 1-3, kang2024clinicalandgenetic pages 1-2, merdlerrabinowicz2019fetuinadeficiencyis pages 3-4)

A verbatim abstract for the foundational APMR1 article was not present in the retrieved full-text evidence. To avoid fabricating quotations, its findings have been accurately paraphrased rather than placed in quotation marks. The available 2024 abstract describes APMR disorders as involving congenital alopecia and variable intellectual disability, but that article concerns APMR4 and should not be used as direct evidence for AHSG causality. (kang2024clinicalandgenetic pages 1-2)

References

  1. (sailani2017associationofahsg pages 4-7): M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136:287-296, Jan 2017. URL: https://doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 16 citations and is from a peer-reviewed journal.

  2. (sailani2017associationofahsg pages 1-3): M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136:287-296, Jan 2017. URL: https://doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 16 citations and is from a peer-reviewed journal.

  3. (sailani2017associationofahsg pages 3-4): M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136:287-296, Jan 2017. URL: https://doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 16 citations and is from a peer-reviewed journal.

  4. (kang2024clinicalandgenetic pages 1-2): Qingyun Kang, Hui Kang, Jingwen Tang, Miao Wang, Haojiang Jiang, Ze-shu Ning, and Liwen Wu. Clinical and genetic analyses of apmr4 syndrome caused by novel biallelic lss variants. Frontiers in Neuroscience, May 2024. URL: https://doi.org/10.3389/fnins.2024.1301865, doi:10.3389/fnins.2024.1301865. This article has 3 citations and is from a peer-reviewed journal.

  5. (sailani2017associationofahsg pages 7-8): M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136:287-296, Jan 2017. URL: https://doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 16 citations and is from a peer-reviewed journal.

  6. (sailani2017associationofahsg pages 8-9): M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136:287-296, Jan 2017. URL: https://doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 16 citations and is from a peer-reviewed journal.

  7. (merdlerrabinowicz2019fetuinadeficiencyis pages 3-4): Rona Merdler-Rabinowicz, Anna Grinberg, Jeffrey M. Jacobson, Ido Somekh, Christoph Klein, Atar Lev, Salama Ihsan, Adib Habib, Raz Somech, and Amos J. Simon. Fetuin-a deficiency is associated with infantile cortical hyperostosis (caffey disease). Pediatric Research, 86:603-607, Jul 2019. URL: https://doi.org/10.1038/s41390-019-0499-0, doi:10.1038/s41390-019-0499-0. This article has 21 citations and is from a domain leading peer-reviewed journal.

  8. (merdlerrabinowicz2019fetuinadeficiencyis pages 4-5): Rona Merdler-Rabinowicz, Anna Grinberg, Jeffrey M. Jacobson, Ido Somekh, Christoph Klein, Atar Lev, Salama Ihsan, Adib Habib, Raz Somech, and Amos J. Simon. Fetuin-a deficiency is associated with infantile cortical hyperostosis (caffey disease). Pediatric Research, 86:603-607, Jul 2019. URL: https://doi.org/10.1038/s41390-019-0499-0, doi:10.1038/s41390-019-0499-0. This article has 21 citations and is from a domain leading peer-reviewed journal.

  9. (merdlerrabinowicz2019fetuinadeficiencyis pages 5-5): Rona Merdler-Rabinowicz, Anna Grinberg, Jeffrey M. Jacobson, Ido Somekh, Christoph Klein, Atar Lev, Salama Ihsan, Adib Habib, Raz Somech, and Amos J. Simon. Fetuin-a deficiency is associated with infantile cortical hyperostosis (caffey disease). Pediatric Research, 86:603-607, Jul 2019. URL: https://doi.org/10.1038/s41390-019-0499-0, doi:10.1038/s41390-019-0499-0. This article has 21 citations and is from a domain leading peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 6
Resolved 3
Unresolved (possible confabulation) 3
Unverifiable 0
References weighed for topical relevance 3
On topic 1
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.1007/s00439-016-1756-5](https://doi.org/10.1007/s00439-016-1756-5 (2 mentions) - Identifier did not resolve to a record
  • DOI:10.3389/fnins.2024.1301865](https://doi.org/10.3389/fnins.2024.1301865 (2 mentions) - Identifier did not resolve to a record
  • DOI:10.1038/s41390-019-0499-0](https://doi.org/10.1038/s41390-019-0499-0 (2 mentions) - Identifier did not resolve to a record